about
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia BThe cost of severe haemophilia in Europe: the CHESS study.BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia BClinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A.Hemophilia B: molecular pathogenesis and mutation analysis.Pathophysiology of Hemophilic Arthropathy.Emerging drugs for hemophilia B.Current management of hemophilia B: recommendations, complications and emerging issues.The current status of prophylactic replacement therapy in children and adults with haemophilia.Causes of Death Among 379 Patients With Hemophilia: A Developing Country's Report.Determining the health-related quality of life in individuals with haemophilia in developing economies: results from the Brazilian population.European retrospective study of real-life haemophilia treatment.Influencing factors on the functional level of haemophilic patients assessed by FISH.Haemophilia B is clinically less severe than haemophilia A: further evidence.Effect of moderate intensity exercise on haemostatic capacity in adults with haemophilia A and B: pilot study.BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.Similar bleeding phenotype in young children with haemophilia A or B: a cohort study.Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?Hemophilia B acquired through liver transplantation.The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B
P2860
Q28078281-AB3A2F8B-3F99-4C40-8052-DD65B8B4A015Q33750095-6D40BC3F-0D07-4132-9E2C-C8378D7BE185Q34348566-0549A330-53E8-4F08-A199-06B036605BCCQ35818302-4A635F1B-4748-4C8C-97CF-953B4094E932Q35832802-358191A5-A7A3-4662-80EC-09E4D52E4EA1Q36414215-B11161AA-4C81-49D6-B6B3-ABE0345F98A0Q38237476-5E874A1D-B7DA-4554-BD4B-9A8A17C42449Q38238972-A4120064-F639-4D74-9C5C-F0108160A0DEQ38394904-9F7C3F03-D1BC-417C-9C08-860E85254557Q38706471-311858F2-6769-4287-8D30-2EBBF6CCC855Q39120920-9FAAE872-D7B9-4648-8D0A-6099FF4A8700Q39268322-FD5D3A24-2B16-4FFE-AB85-343B32A6689BQ45388131-291DBC82-64CE-4FCA-8C26-C917457659F7Q45859023-B52797E1-FDBB-48D5-976D-7F6FB4C443C3Q45863862-96596EE2-3CE1-4ABF-A325-559AAF5277F2Q45865134-AEBDA4D2-5B6A-4909-B859-A02D63D665D9Q45865672-B273F794-75B7-40CF-8618-81806AD85C02Q45869919-0E50A732-304C-4E1F-BF1E-A385D5D31931Q45880307-23496467-2170-4A8D-9820-CA62B9A5605BQ58706077-A3A624FF-F93E-45F9-90CF-C7026D4257FD
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Is haemophilia B less severe than haemophilia A?
@en
type
label
Is haemophilia B less severe than haemophilia A?
@en
prefLabel
Is haemophilia B less severe than haemophilia A?
@en
P2860
P921
P356
P1433
P1476
Is haemophilia B less severe than haemophilia A?
@en
P2093
M Franchini
P M Mannucci
P2860
P304
P356
10.1111/HAE.12133
P577
2013-03-21T00:00:00Z